Acute Bacterial Skin and Skin Structure Infections

Global Acute Bacterial Skin and Skin Structure Infections Market to Reach US$1.5 Billion by 2030

The global market for Acute Bacterial Skin and Skin Structure Infections estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Community-Acquired ABSSI, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Hospital- Acquired ABSSI segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$349.8 Million While China is Forecast to Grow at 5.2% CAGR

The Acute Bacterial Skin and Skin Structure Infections market in the U.S. is estimated at US$349.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$291.5 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Acute Bacterial Skin and Skin Structure Infections Market – Key Trends & Drivers Summarized

What Are ABSSSIs, and Why Is Their Management Crucial in Modern Healthcare?

Acute bacterial skin and skin structure infections encompass a broad spectrum of serious bacterial infections, including cellulitis, abscesses, and wound infections. These conditions often result from pathogens such as Staphylococcus aureus, including its methicillin-resistant strain (MRSA), and Streptococcus pyogenes, posing significant challenges for effective treatment. The management of ABSSSIs has gained critical importance due to their rising prevalence, driven by factors such as an aging global population, the increasing prevalence of diabetes, and the growing number of surgical procedures. These infections, if not treated promptly, can lead to severe complications, including sepsis and prolonged hospital stays, placing a significant burden on healthcare systems worldwide. The development of targeted therapies and advanced antibiotics has become essential in combating ABSSSIs, offering solutions that address antimicrobial resistance while ensuring rapid and effective patient recovery.

How Are Innovations in Antibiotic Therapies Revolutionizing ABSSSI Treatment?

The treatment landscape for ABSSSIs has witnessed substantial innovation, with the development of new-generation antibiotics and novel delivery systems aimed at improving efficacy and patient outcomes. Traditional antibiotics such as vancomycin and daptomycin continue to be widely used; however, the emergence of resistant strains has necessitated the introduction of advanced alternatives. Novel agents like tedizolid, dalbavancin, and oritavancin have shown promising results, offering enhanced activity against resistant pathogens, reduced dosing frequency, and fewer side effects. Additionally, combination therapies have emerged as effective strategies to combat multi-drug-resistant organisms by targeting different bacterial mechanisms. Innovations in drug delivery, such as long-acting formulations and injectable antibiotics, have improved patient compliance and reduced hospital admissions. Moreover, advancements in rapid diagnostic tools have facilitated the early identification of pathogens, enabling personalized treatment approaches and minimizing the overuse of broad-spectrum antibiotics. These developments are significantly enhancing the standard of care for ABSSSI patients.

Which Regions and Patient Demographics Are Driving Market Demand?

The demand for ABSSSI treatments varies significantly across regions, shaped by differences in healthcare access, prevalence of resistant pathogens, and disease awareness. North America and Europe are leading markets for ABSSSI therapies, driven by advanced healthcare infrastructure, high diagnostic rates, and a strong focus on antimicrobial stewardship. The growing incidence of hospital-acquired infections and surgical site infections in these regions has further fueled the adoption of novel antibiotics and targeted therapies. The Asia-Pacific region, however, is emerging as a key growth market due to its large population base, rising healthcare expenditures, and increasing prevalence of infectious diseases. Countries like China and India are particularly prominent, with expanding healthcare infrastructures and heightened awareness of antibiotic resistance challenges. Within patient demographics, individuals with compromised immune systems, such as those with diabetes, HIV, or undergoing chemotherapy, represent a significant portion of the market demand. Additionally, the aging population and the growing number of patients with chronic wounds and pressure ulcers are contributing to the increased prevalence of ABSSSIs worldwide.

What Factors Are Driving Growth in the ABSSSI Market?

The growth in the Acute Bacterial Skin and Skin Structure Infections market is driven by several factors, including the increasing prevalence of drug-resistant pathogens, advancements in antibiotic development, and growing awareness of infectious disease management. The rise of resistant strains such as MRSA has heightened the demand for innovative therapies that address the limitations of traditional antibiotics. Advances in targeted therapies, including new antibiotics and combination treatments, have provided effective solutions to combat challenging infections. The increasing prevalence of chronic conditions such as diabetes, which predispose individuals to ABSSSIs, has also fueled market growth. Expanding healthcare access in emerging markets, combined with government initiatives to combat antimicrobial resistance, has further supported the adoption of advanced treatment solutions. Additionally, investments in R&D by pharmaceutical companies and the introduction of faster diagnostic tools have enhanced early detection and treatment efficacy, ensuring sustained growth in the global ABSSSI market.

SCOPE OF STUDY:

The report analyzes the Acute Bacterial Skin and Skin Structure Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Infection Type (Community-Acquired ABSSI, Hospital- Acquired ABSSI); Route of Administration (Oral Administration, Parenteral Administration, Topical Administration); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 25 Featured) -

• AbbVie, Inc.
• Basilea Pharmaceutica Ltd.
• Cipher Pharmaceuticals Inc.
• Cumberland Pharmaceuticals Inc.
• Melinta Therapeutics LLC
• MicuRx Pharmaceuticals, Inc.
• Nabriva Therapeutics plc
• Paladin Labs Inc.
• Paratek Pharmaceuticals, Inc.
• Recce Pharmaceuticals Ltd.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.